micro-community-banner
  • Saved

1yr
Cardiovascular disease: Mitochondrial dynamics and mitophagy crosstalk mechanisms with novel programmed cell death and macrophage polarisation

Cardiovascular disease: Mitochondrial dynamics and mitophagy crosstalk mechanisms with novel programmed cell death and macrophage polarisation

Source : https://pubmed.ncbi.nlm.nih.gov/38909638/

Several cardiovascular illnesses are associated with aberrant activation of cellular pyroptosis, ferroptosis, necroptosis, cuproptosis, disulfidptosis, and macrophage polarisation as hallmarks contributing to vascular damage and abnormal cardiac function. Meanwhile, these...

The conclusion effectively underscores the critical role of mitochondrial dynamics and mitophagy in modulating various cellular dysfunctions and macrophage polarization linked to cardiovascular diseases, advocating for comprehensive research to advance therapeutic strategies.

  • Saved

1yr
An "Inclisiran First" Strategy vs Usual Care in Patients With Atherosclerotic Cardiovascular Disease

An "Inclisiran First" Strategy vs Usual Care in Patients With Atherosclerotic Cardiovascular Disease

Source : https://pubmed.ncbi.nlm.nih.gov/38593947/

An "inclisiran first" implementation strategy led to greater LDL-C lowering compared with usual care without discouraging statin use or raising new safety concerns. (A Randomized, Multicenter, Open-label Trial Comparing the...

An "inclisiran first" implementation strategy led to greater LDL-C lowering compared with usual care without discouraging statin use or raising new safety concerns.

  • Saved

1yr
Progress of uric acid in cardiovascular disease

Progress of uric acid in cardiovascular disease

Source : https://pubmed.ncbi.nlm.nih.gov/38633361/

Due to the global prevalence of hyperuricemia (HUA), there is growing interest in research on uric acid (UA). HUA is a common condition that has various adverse consequences, including gout...

Serum uric acid's significant implications in cardiovascular diseases (CVD), including atrial fibrillation (AF) and coronary heart disease (CHD). Lowering UA levels could potentially impact CVD management significantly.

  • Saved

1yr
Cardiovascular disease: extraintestinal manifestation of inflammatory bowel disease

Cardiovascular disease: extraintestinal manifestation of inflammatory bowel disease

Source : https://pubmed.ncbi.nlm.nih.gov/38712363/

Inflammatory bowel disease (IBD) is a spectrum of diseases characterized by the interplay of the aberrant immune system, genetic factors, environmental factors, and intestinal microbiota, resulting in relapsing inflammation of...

The complex interplay of immune dysregulation, chronic inflammation, and intestinal dysbiosis in inflammatory bowel disease (IBD) increases the risk of cardiovascular diseases (CVD). Lifestyle changes and medication adherence are crucial for mitigating this risk.

  • Saved

1yr
Breakthrough Insights in Hematologic Malignancies from EHA 2024: STIMULUS-MDS2 and STARGLOW Trials

Dr. Amer Zeidan from Yale University discusses the STIMULUS-MDS2 study presented at the European Hematology Association meeting in Madrid. This large, randomized phase 3 trial examined the efficacy of combining azacitidine with the anti-TIM3 antibody sabatolimab in patients with high-risk MDS. Although the primary endpoint of overall survival was not met, the combination showed a trend toward improvement in survival and higher complete remission rates.

Dr. Jeremy Abramson from Massachusetts General Hospital shares results from the STARGLOW trial, which evaluated glofitamab with gemcitabine and oxaliplatin in relapsed refractory diffuse large B-cell lymphoma. The trial demonstrated significant improvements in overall survival, progression-free survival, and complete response rates, positioning glofitamab as a promising second-line therapy for DLBCL.